ABOUT US
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.
We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.
VIDEOS
FEATURED PRODUCTS
-
MabSelect™ VL resin — protein L resin for affinity capture of antibody Fabs, bispecifics, and other variants containing a kappa light chain.
-
Supplements cell culture with amino acids, vitamins, and glucose and manufactured to meet cGMP manufacturing standards and QC specifications.
-
ÄKTA™ chromatography systems can handle both simple and complex purification tasks and accelerate daily routines. All systems are controlled by UNICORN™ software, a common control platform and user interface for all scales of operation.
-
Cytiva provides filtration solutions and support for integrated bioprocessing applications at every step and every scale of the drug development, validation and manufacturing process.
-
We offer a range of systems, accessories, and reagents for label-free analysis using microcalorimetry or surface plasmon resonance (SPR). These techniques provide information-rich, real time data without the use of labels.
-
ÄKTA pure™ is a flexible and intuitive chromatography system for fast purification of proteins, peptides, and nucleic acids from microgram levels to tens of grams of target product in research scale applications. ÄKTA pure™ is a reliable system where hardware and UNICORN™ system control software are designed to work together with columns and media to meet any purification challenge.
-
ÄKTA start™ is a preparative chromatography system for laboratory-scale protein purification. ÄKTA start™ is designed as a stand-alone system, with an intuitive design, simple flow path, and user-friendly interface. With ÄKTA start™, it is easy to purify a wide variety of proteins using built-in quick start methods or predefined templates, or by creating your own methods.
-
Biacore protein interaction and stability analysis systems characterized molecules in terms of their specificity and selectivity of interaction, on and off rates (kinetics), and binding strength (affinity).
BROCHURES AND DATASHEETS
WEBINARS
APPLICATION NOTES
- Alkaline Stability Of Modern Protein A Chromatography Resins
- AAV Full/Empty Capsid Separation Using Mechanistic Modeling
- Recombinant Protein Purification Optimization With HIC
- Explore Protein Interactions Beyond Affinity To Boost Your Academic Research
- Capture Of Histidine-Tagged Molecules Using Biacore His Capture Kit
- Chromatography Method For Purifying Infectious Virus Particles
- Purifying Tagged Proteins Using A Small And Compact LC System
- Epitope Binning: A Critical Step In Antibody Selection
- EDGE Confocal Imaging Technology
- Converting From ELISA To Biacore SPR Assays
CONTACT INFORMATION
Cytiva
100 Results Way
Marlborough, MA 08855-1327
UNITED STATES
Phone: 800-526-3593
FEATURED ARTICLES
-
Advanced spare parts planning can reduce downtime. Learn why precise component specifications matter and how seemingly identical parts can differ significantly in quality, performance, and failure risk.
-
Preventive maintenance helps reduce equipment failures. Learn why regular service schedules are becoming even more important as biopharmaceutical production shifts toward continuous processing.
-
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
APAC is rapidly advancing its role in the global therapeutics landscape, fueled by faster development models. Learn how this momentum is reshaping expectations for innovation and commercialization.
-
Accelerate drug development and reduce risk with parallel operations. Learn how leveraging CDMO partnerships while building internal capabilities can cut costs and speed your path to market.
-
Accelerating biologics development requires more than speed. Discover how the right CDMO partnership can streamline processes and help you reach the market faster without sacrificing control.
-
Transparency and collaboration with a CDMO are vital for reducing risk and protecting IP. Discover four essential practices, from clear communication to IP safeguards, that help build trust.
-
Parallel operations with a CDMO can reduce risk and accelerate timelines by enabling simultaneous process development and manufacturing. Learn how this approach supports facility design.
-
See how biotech innovation is accelerating drug discovery through AI, miniaturized workflows, and collaborative technologies to reshape how therapies are developed and delivered.
-
Advanced therapies are nearing mainstream adoption, with cell, mRNA, and oligonucleotide treatments expanding into broader indications. Learn what’s driving this shift and what manufacturers must do.